CJC-1295 with DAC 10mg
Long-Acting GHRH Analogue for Sustained GH Elevation Research
CJC-1295 with DAC uses a Drug Affinity Complex to covalently bind serum albumin after injection, extending its half-life to 6-8 days and producing sustained baseline GH elevation rather than pulsatile release.
Long-Acting GHRH Analogue for Sustained GH Elevation Research
The DAC (Drug Affinity Complex) modification allows CJC-1295 to bind to lysine residues on albumin in vivo, creating a long-lasting GHRH depot that produces continuous GH elevation — a fundamentally different research profile from the No DAC variant.
As one of the most studied compounds in the growth & body comp research space, CJC-1295 DAC has attracted sustained scientific interest across Long-acting GH research, Sustained IGF-1 elevation studies, Comparison vs. pulsatile GH protocols. Peer-reviewed evidence indicates that 6-8 day half-life vs. 30 min for No DAC, which has positioned CJC-1295 DAC as a reference standard for researchers exploring long-acting gh research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
CJC-1295 DAC Documented Benefits: 3 Documented Mechanisms
Extended Half-Life
6-8 day half-life via albumin binding produces sustained GH elevation with once-weekly dosing research.
Continuous GH Elevation
Produces tonic rather than pulsatile GH/IGF-1 elevation for different metabolic research endpoints.
Convenient Dosing Research
Once or twice weekly injection schedule for sustained GH research protocols.
How CJC-1295 DAC Works: Molecular Mechanism & Pathway
GHRH analogue with maleimidopropionic acid DAC modification that reacts with albumin Lys-residues in vivo, creating a long-acting GHRH-albumin conjugate with 6-8 day half-life.
The 3 primary research pathways identified for CJC-1295 DAC — Extended Half-Life, Continuous GH Elevation, Convenient Dosing Research — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that sustained IGF-1 elevation in clinical studies, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, CJC-1295 DAC's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
CJC-1295 DAC is routinely studied alongside Ipamorelin and CJC-1295 in growth & body comp-focused compound panels. Researchers investigating long-acting gh research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that distinct continuous vs. pulsatile GH profile has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All CJC-1295 DAC research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- 6-8 day half-life vs. 30 min for No DAC
- Sustained IGF-1 elevation in clinical studies
- Distinct continuous vs. pulsatile GH profile
Ideal For
- Long-acting GH research
- Sustained IGF-1 elevation studies
- Comparison vs. pulsatile GH protocols
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on CJC-1295 DAC. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
6-8 day half-life vs. 30 min for No DAC
Sustained IGF-1 elevation in clinical studies
Distinct continuous vs. pulsatile GH profile
Third-Party Verified Every Batch
Each vial of CJC-1295 DAC is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
